UO
Therapeutic Areas
Crestone Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CRS3123 | Clostridioides difficile infection (CDI) | Phase 2 |
| Undisclosed Program | Antibiotic-resistant Gram-positive infections (e.g., MRSA, VRE) | Preclinical |
| Drug | Indication | Phase |
|---|---|---|
| CRS3123 | Clostridioides difficile infection (CDI) | Phase 2 |
| Undisclosed Program | Antibiotic-resistant Gram-positive infections (e.g., MRSA, VRE) | Preclinical |